LOS ANGELES, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vistagen Therapeutics, Inc., (“Vistagen” or the "Company") (NASDAQ: VTGN) investors of a class action on behalf of investors that bought securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). Vistagen investors have until March 16, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss the ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's clinical trial results [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Vistagen between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Vistagen and its executives made false statements regarding the likelihood of success in the PALISADE-3 clinical trial, which misled investors and caused them to purchase shares at inflated prices [5]. Group 2: Clinical Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study for fasedienol failed to meet its primary efficacy endpoint, leading to a significant stock price drop of over 81%, opening at $0.88 per share [6]. - The study did not demonstrate statistically significant improvement in anxiety reduction compared to placebo, which contradicted previous positive assertions made by the company [5][6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [8].

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183185&from=3 CLASS ...

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/vistagen-therapeu ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026. SO WHAT: If you purchased Vistagen Therapeutics common stock du ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol, leading to inflated stock prices during the class period from April 1, 2024, to December 16, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen's management made positive assertions about the success of fasedienol based on prior clinical trial results, which misled investors [5]. - It is alleged that while promoting the drug's potential, the company concealed material adverse facts about the Phase 3 PALISADE-3 trial, resulting in shareholders purchasing stock at artificially inflated prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron D ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from April 1, 2024, to December 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Vistagen securities during the specified Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements regarding the development of fasedienol and the Phase 3 PALISADE‑3 trial, which faced significant adverse facts [3]. - Defendants are accused of disseminating false information and concealing material adverse data about the PALISADE‑3 study's design, execution, and clinical results [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by March 16, 2026, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol, leading to inflated stock prices during the class period from April 1, 2024, to December 16, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen's defendants made positive assertions about the success of fasedienol based on prior clinical trial results, which misled investors [5]. - It is alleged that while promoting fasedienol's potential, the defendants concealed material adverse facts about the Phase 3 PALISADE-3 trial, resulting in shareholders purchasing stock at artificially inflated prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7].